NCT00465725View on ClinicalTrials.gov

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Bladder CancerBreast CancerColorectal CancerGastrointestinal NeoplasmHead and Neck CancerLung CancerOvarian CancerPancreatic CancerProstate Cancer
Interventions
DRUG

Picoplatin

The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.

Trial Locations (3)

30342

Georgia Cancer Specialists, Atlanta

89135

Nevada Cancer Institute, Las Vegas

98405

Northwest Medical Specialties, Tacoma

Sponsors
All Listed Sponsors
lead

Poniard Pharmaceuticals

INDUSTRY